Overview

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Status:
Not yet recruiting

Trial end date:
2026-04-13

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Durvalumab
Tremelimumab